Concepedia

Maura A. Kraynak

MA

13

Publications

943

Citations

13

H-Index

1996

Active since

Affiliations

The University of Texas Health Science Center at San Antonio(Current)

The University of Texas at San Antonio

Brooke Army Medical Center

Maura A. Kraynak is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, pharmacotherapy, and oncology.

Top concepts

Publications per year

1996–2002

13

Publications

13

Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer

John Nemunaitis, Jon Holmlund, Maura A. Kraynak et al. · Journal of Clinical Oncology · 1999 · 172 citations

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

Eric K. Rowinsky, Lee Smith, Y M Wang et al. · Journal of Clinical Oncology · 1998 · 146 citations

Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors

Ronald Drengler, John G. Kuhn, Larry J. Schaaf et al. · Journal of Clinical Oncology · 1999 · 94 citations

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

Miguel A. Villalona‐Calero, S. Gail Eckhardt, Geoffrey R. Weiss et al. · PubMed · 2002 · 82 citations

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

Mace L. Rothenberg, A. Sharma, Geoffrey R. Weiss et al. · Annals of Oncology · 1998 · 76 citations

, , +8

Rows per page

1–5 of 13